ClinicalTrials.gg
Not yet recruitingNCT07488195Updated Oct 26, 2026

A Study Of Phototherapy In Patients With Dementia To Improve BPSD

An interventional study of Phototherapy in Dementia, sponsored by Mayo Clinic. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

How we know

Updated Oct 26, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Dementia by Mayo Clinic — 6 open to participants now, 6 under way, none of them phase 3. Dementia · Mayo Clinic.

Planned enrollment
7th of 14
70 · median 60
Started
2026
the only one that year
No phase
8 of 14
1 open now
Registered
14th of 14
by date

Among the 14 studies in Dementia by Mayo Clinic, this one is the 7th largest by planned enrollment, is the only one that started in 2026, is one of 8 with no phase, and was the 14th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

6 of the 14 studies in Dementia by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Dementia by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this research is to determine whether the use of phototherapy can help reduce behavioral and psychological symptoms, including agitation in people with dementia.

03

Conditions studied

  • Dementia

Browse trials for

Keywords

  • Phototherapy
  • Complex dementia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients admitted on the inpatient Domitilla 3D or 4D unit.
  • Documented diagnosis of dementia or suspected major neurocognitive disorder.
  • Presence of BPSD symptoms either clinician documented in EHR or assessed through CMAI-O form
  • Have patient consent or have a LAR able to sign the consent on behalf of the patient.

Exclusion criteria

Exclusion Criteria:

  • Macular degeneration, blindness, or photosensitivity
  • Patients that do not have capacity to consent and do not have a legally authorized representative to consent on their behalf
  • Recent eye surgery
  • Bipolar disorder
  • Pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Phototherapy

    Patients in the phototherapy arm will receive bright light therapy for 60 minutes, 3 times per day for 5 days.

    Other: Phototherapy

  • No intervention
    Standard of Care

    Patients in the standard of care group will not receive an intervention.

Interventions

  • OtherPhototherapy

    Bright light therapy will be provided via the Verilux HappyLight. The unit will be placed on a mobile bedside table, at eye level, 60 cm from the patient. Patients will receive phototherapy in 60 minute sessions, 3 times daily for 5 days.

06

What researchers measure

Primary outcomes

  1. Feasibility of 5-day phototherapy protocol

    Feasibility will be defined as the percentage of eligible patients who choose to enroll in the study out of total patients approached.

    Time frame: Day 5

  2. Acceptability of 5-day phototherapy protocol

    Accessibility will be defined as the percentage of study participants to complete at least one session per day of the 5-day protocol

    Time frame: Day 5

  3. Tolerability of 5-day phototherapy protocol

    Tolerability will be defined as percentage of patients to rate phototherapy as 'very tolerable' based on being asked "Considering all aspects of your experience, how would you rate the overall tolerability of the phototherapy?" The response options are: very tolerable, somewhat tolerable, neutral, somewhat intolerable, and very intolerable.

    Time frame: Day 5

Secondary outcomes

  1. Sleep duration

    Sleep duration will be reported by nursing staff in hours.

    Time frame: Day 5

07

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
    • Melanie Gentry, MD · Contact507-284-2933
    • Donna Lawson · Contact507-255-7975
    • Stephanie P. Chambers, APRN, CNS · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.

Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 2 months is below that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 23, 2026
StartEst.
Oct 20, 2026was Aug 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 15, 2026→Oct 20, 2026
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Start date Aug 15, 2026→Oct 20, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07488195
Lead sponsor
Mayo Clinic
Responsible party
Stephanie Chambers (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Mar 23, 2026
Start date
Oct 20, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 26, 2026

Study contacts

Melanie Gentry, MD
Contact
gentry.melanie@mayo.edu
507-284-2933
Donna Lawson
Contact
lawson.donna@mayo.edu
507-255-7975
Stephanie P. Chambers, APRN, CNS
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion